BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 10657849)

  • 1. Evidence for complement-dependent and -independent inhibition of insulin secretion from clonal beta-cells incubated in the presence of sera of newly diagnosed IDDM patients.
    Conroy SJ; Abdel-Wahab YH; Caraher EM; Byrne PM; Murphy E; Nolan J; Flatt PR; Newsholme P
    J Endocrinol; 2000 Feb; 164(2):139-47. PubMed ID: 10657849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for enhanced rates of complement activation in serum from patients with newly diagnosed insulin-dependent diabetes mellitus exposed to rat islet cells and complement-dependent induction of islet cell apoptosis.
    Caraher EM; Conroy SJ; Newsholme P
    J Endocrinol; 1999 Jul; 162(1):143-53. PubMed ID: 10396031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for a sustained increase in clonal beta-cell basal intracellular Ca2+ levels after incubation in the presence of newly diagnosed Type-1 diabetic patient sera. Possible role in serum-induced inhibition of insulin secretion.
    Conroy SJ; Green I; Dixon G; Byrne PM; Nolan J; Abdel-Wahab YH; McClenaghan N; Flatt PR; Newsholme P
    J Endocrinol; 2002 Apr; 173(1):53-62. PubMed ID: 11927384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of sera obtained from children with insulin-dependent diabetes mellitus on cultivated islet cells: cytotoxicity and insulin release.
    Sadovnikova NV; Pankov YA; Fedotov VP; Czernushkina AV; Zhukovsky MA; Shcherbacheva LN
    Exp Clin Endocrinol; 1989 May; 93(2-3):166-72. PubMed ID: 2673810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glutamic acid decarboxylase autoantibodies in preclinical insulin-dependent diabetes.
    De Aizpurua HJ; Wilson YM; Harrison LC
    Proc Natl Acad Sci U S A; 1992 Oct; 89(20):9841-5. PubMed ID: 1409709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of islet cell surface antibodies using cloned beta cells and comparison of their incidence with that of islet cell cytoplasmic antibodies.
    Grant AM; Harrison DE; Moysey L; Smith D; Ashcroft SJ
    Diabetes Res; 1985 Sep; 2(5):225-9. PubMed ID: 3905186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement-fixing Islet cell antibodies from some diabetic patients alter insulin release in vitro.
    Sai P; Boitard C; Debray-Sachs M; Pouplard A; Assan R; Hamburger J
    Diabetes; 1981 Dec; 30(12):1051-7. PubMed ID: 7030831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibodies to glutamic acid decarboxylase in Australian children with insulin-dependent diabetes mellitus and their first-degree relatives.
    Chen QY; Rowley MJ; Byrne GC; Jones TW; Tuomi T; Knowles WJ; Zimmet PZ; Mackay IR
    Pediatr Res; 1993 Dec; 34(6):785-90. PubMed ID: 8108194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic islet cell cytoplasmic antibody in diabetes is represented by antibodies to islet cell antigen 512 and glutamic acid decarboxylase.
    Myers MA; Rabin DU; Rowley MJ
    Diabetes; 1995 Nov; 44(11):1290-5. PubMed ID: 7589826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoantibodies associated with presymptomatic insulin-dependent diabetes mellitus in women.
    Whittingham S; Byron SL; Tuomilehto J; Zimmet PZ; Myers MA; Vidgren G; Rowley MJ; Feeney SJ; Koskela P; Tuomilehto-Wolf E; Mackay IR
    Diabet Med; 1997 Aug; 14(8):678-85. PubMed ID: 9272595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytoplasmic islet cell antibodies recognize distinct islet antigens in IDDM but not in stiff man syndrome.
    Richter W; Seissler J; Northemann W; Wolfahrt S; Meinck HM; Scherbaum WA
    Diabetes; 1993 Nov; 42(11):1642-8. PubMed ID: 8405707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GAD autoantibodies in IDDM, stiff-man syndrome, and autoimmune polyendocrine syndrome type I recognize different epitopes.
    Björk E; Velloso LA; Kämpe O; Karlsson FA
    Diabetes; 1994 Jan; 43(1):161-5. PubMed ID: 7505244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human monoclonal islet cell antibodies from a patient with insulin-dependent diabetes mellitus reveal glutamate decarboxylase as the target antigen.
    Richter W; Endl J; Eiermann TH; Brandt M; Kientsch-Engel R; Thivolet C; Jungfer H; Scherbaum WA
    Proc Natl Acad Sci U S A; 1992 Sep; 89(18):8467-71. PubMed ID: 1382289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of autoimmune serological reactions in rodent models of insulin dependent diabetes mellitus.
    Mackay IR; Bone A; Tuomi T; Elliott R; Mandel T; Karopoulos C; Rowley MJ
    J Autoimmun; 1996 Dec; 9(6):705-11. PubMed ID: 9115572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro inhibition of insulin release mediated by sera with complement-fixing islet cell antibodies belonging to normal first degree relatives of patients with type 1 diabetes.
    Sensi M; Zuccarini O; Spencer KM; Beales P; Pujol-Borrell R; Pozzilli P
    Diabetes Res; 1985 Jan; 2(1):1-4. PubMed ID: 3888494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of autoantibodies to the 65- and 67-kD isoforms of glutamate decarboxylase in insulin-dependent diabetes mellitus.
    Seissler J; Amann J; Mauch L; Haubruck H; Wolfahrt S; Bieg S; Richter W; Holl R; Heinze E; Northemann W
    J Clin Invest; 1993 Sep; 92(3):1394-9. PubMed ID: 8376591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoantigens in insulin-dependent diabetes mellitus: molecular cloning and characterization of human IA-2 beta.
    Li Q; Borovitskaya AE; DeSilva MG; Wasserfall C; Maclaren NK; Notkins AL; Lan MS
    Proc Assoc Am Physicians; 1997 Jul; 109(4):429-39. PubMed ID: 9220540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Genetic engineering approaches to the study of insulin-dependent diabetes mellitus markers].
    Pankov IuA
    Vopr Med Khim; 1997; 43(5):349-55. PubMed ID: 9446325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies to glutamic acid decarboxylase and insulin-dependent diabetes in patients with autoimmune polyendocrine syndrome type I.
    Tuomi T; Björses P; Falorni A; Partanen J; Perheentupa J; Lernmark A; Miettinen A
    J Clin Endocrinol Metab; 1996 Apr; 81(4):1488-94. PubMed ID: 8636356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do glutamic acid decarboxylase antibodies improve the prediction of IDDM in first-degree relatives at risk for IDDM?
    Schmidli RS; Colman PG; Harrison LC
    J Autoimmun; 1994 Dec; 7(6):873-9. PubMed ID: 7888043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.